How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

779 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial (PubMed)

with vascular damage to the cholinergic system will in turn respond to a cholinergic challenge.The STREAM-VCI is a single center, double blind, three-way cross-over trial among 30 people with VCI, in which subjects received a single dose of galantamine, methylphenidate, or placebo on separate occasions. The most important inclusion criteria were a diagnosis of VCI with a Mini-Mental State Examination score of ≥16 and a Clinical Dementia Rating of 0.5-1.0. For each person, the challenges consisted (...) of a single 16 mg dose of galantamine, 10 mg of methylphenidate, and placebo, in random order on three separate visits. Change in performance in executive functioning and memory was assessed directly after the challenge using standardized neuropsychological tests. We will correlate a positive response to the cholinergic and monoaminergic treatment with differences in structural and functional connectivity at baseline using structural magnetic resonance imaging (MRI), diffusion tension MRI, and resting

Full Text available with Trip Pro

2018 JMIR Research Protocols

182. Strategies for Continued Successful Treatment in Patients with 
Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents (PubMed)

Strategies for Continued Successful Treatment in Patients with 
Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents Alzheimer's disease (AD) is the most common cause of dementia, characterized by a progressive decline in cognition and function. Current treatment options for AD include the cholinesterase inhibitors (ChEIs) donepezil, galantamine, and rivastigmine, as well as the N-methyl-Daspartate receptor antagonist memantine. Treatment guidelines recommend the use

Full Text available with Trip Pro

2018 Current Alzheimer research

183. Activation of α7 Nicotinic Acetylcholine Receptor Ameliorates Zymosan-Induced Acute Kidney Injury in BALB/c Mice (PubMed)

Activation of α7 Nicotinic Acetylcholine Receptor Ameliorates Zymosan-Induced Acute Kidney Injury in BALB/c Mice Zymosan, a natural compound, provokes acute peritonitis and multiple organ dysfunction that affects the kidney, beside other organs via exaggerated inflammatory response. The aim of the present study is to test the role of cholinergic anti-inflammatory pathway (CAP) in alleviating acute kidney injury (AKI) induced by zymosan in BALB/c mice, using galantamine, a cholinesterase (...) inhibitor, known to act via α7 nicotinic acetylcholine receptor (α7 nAChR) to stimulate CAP. Galantamine verified its anti-inflammatory effect by elevating acetylcholine (ACh) level, while abating the interleukin-6/ janus kinase 2 (Y1007/1008)/ signal transducer and activator of transcription 3 (Y705) (IL-6/ pY(1007/1008)-JAK2/ pY705-STAT3) inflammatory axis, with a consequent inhibition in suppressor of cytokine signaling 3 (SOCS3). This effect entails also the nuclear factor-kappa B (p65)/ high

Full Text available with Trip Pro

2018 Scientific reports

184. Screening and analysis of acetyl-cholinesterase (AChE) inhibitors in the context of Alzheimer's disease (PubMed)

carried out virtual screening of drug-like molecules from Chemical Diversity Database particularly CNS-BBB compounds, to identify potential inhibitors using Glide docking program. Top ranking ten compounds, which have lower Glide Score when compared to known drugs (Tacrine and Galantamine) for AChE. For top three molecules MD simulation was carried out and calculated binding free energy. We report the best binding compounds with AChE compared to known drugs (Taine and Galantamine) for AD. We further (...) ligands Tacrine and Galantamine having -119.65 and -142.18 kJ/mol respectively. Thus these molecules can be very novel potential inhibitors against AChE involved in Alzheimer's disease.

Full Text available with Trip Pro

2018 Bioinformation

185. Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy (PubMed)

, among which galantamine is the only naturally occurring substance. However, several plant species producing diverse classes of alkaloids, coumarins, terpenes, and polyphenols have been assessed for their anti-AChE activity, becoming potential candidates for new anti-AD drugs. Therefore, this mini-review aimed to recapitulate last decade studies on the anti-AChE activity of plant species, their respective extracts, as well as isolated compounds. The anti-AChE activity of extracts prepared from 54

Full Text available with Trip Pro

2018 Frontiers in pharmacology

186. Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review (PubMed)

Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review The increasing prevalence of Alzheimer's disease (AD) demands more effective drugs, which are still unclear. The aim of this study is to compare the effectiveness of six drugs, such as donepezil, rivastigmine, galantamine, memantine, huperzine-A, and tacrine, in senior AD patients and identify the most effective one to improve patients' cognitive function.A system of search strategies (...) the trials included.Among the 35 trials included, no obvious heterogeneity (I2=0.0%, P=0.583) was revealed according to the pooled data for cognition in NMA and the mean difference (MD) of memantine (MD=1.7, 95% CI: 0.73, 2.8) showed that the memantine was significantly efficacious in the treatment group in terms of MMSE. Followed by galantamine, huperzine-A, rivastigmine, tacrine, and donepezil.As the first NMA comparing the major drugs in market for AD, our study suggests that memantine might have

Full Text available with Trip Pro

2018 Clinical interventions in aging

187. Open-label, PK and Safety Study in Mild-to-moderate Alzheimer's Disease Patients

at home, senior residential setting, or an institutional setting without the need for continuous (i.e. 24-h) nursing care General health status acceptable for participation in the study Fluency (oral and written) in English or Spanish If receiving memantine, rivastigmine, galantamine or an AChEI, receiving a stable dose for at least 3 months (90 days) before screening and with continuous dosing for at least 3 months. If receiving donepezil, receiving any dose lower than 23 mg once daily. The patient

2018 Clinical Trials

188. Profiling donepezil template into multipotent hybrids with antioxidant properties (PubMed)

Profiling donepezil template into multipotent hybrids with antioxidant properties Alzheimer's disease is debilitating neurodegenerative disorder in the elderly. Current therapy relies on administration of acetylcholinesterase inhibitors (AChEIs) -donepezil, rivastigmine, galantamine, and N-methyl-d-aspartate receptor antagonist memantine. However, their therapeutic effect is only short-term and stabilizes cognitive functions for up to 2 years. Given this drawback together with other

Full Text available with Trip Pro

2018 Journal of enzyme inhibition and medicinal chemistry

189. ANAVEX2-73 Study in Parkinson's Disease Dementia

, dopamine agonists, MAO-B inhibitors, or the COMT inhibitor entacapone), which has been stable for at least 4 weeks prior to Baseline. Treatment with cholinesterase inhibitor (rivastigmine, donepezil and galantamine (Exelon®, Aricept®, or Reminyl®) will be permitted, provided the dose has been stable for a minimum of 8 weeks prior to randomization. Subjects with history of depression on antidepressant medications will be allowed if depression is controlled and they have been on a stable daily dose

2018 Clinical Trials

190. Touchscreen Technology and Art for People With Dementia in Care Homes

, Icchp 2016, Pt I, 9758, 509-514. doi:10.1007/978-3-319-41264-1_69 Mihailidis, A., Blunsden, S., Boger, J., Richards, B., Zutis, K., Young, L., & Hoey, J. (2010). Towards the development of a technology for art therapy and dementia: Definition of needs and design constraints. The Arts in Psychotherapy, 37(4), 293-300. NICE. (2011). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Retrieved from https://www.nice.org.uk/guidance/ta217 Smith, S. K. (2015

2018 Clinical Trials

191. Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias

series and reports were excluded. Included patients had Alzheimer’s Disease of varying severity. Some patients had comorbidities (as reported in the review). Mean ages of patients ranged from 71.5 to 78.4 years. Most patients were female. Cholinesterase inhibitors included donepezil, rivastigmine and galantamine at varying doses. Two reviewers screened studies for inclusion; discrepancies were resolved through consensus. Assessment of study quality Randomised controlled trials (RCTs) were assessed

Full Text available with Trip Pro

2012 DARE.

192. Therapeutic interventions for aphasia initiated more than six months post stroke: a review of the evidence

, donepezil, memantine and galantamine were found to be effective in one RCT each. However, two RCTs demonstrated that bromocriptine was not effective. Three RCTs assessed brain stimulation techniques and found that both repetitive transcranial magnetic stimulation (rTMS) and anodal transcranial direct current stimulation (tDCS) improved naming abilities and lexical production. Two RCTs demonstrated that constraint-induced aphasia therapy was effective. Authors' conclusions There was evidence to support

2012 DARE.

193. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease

valid, but the clinical evidence was weak. Further studies are needed to support the authors’ findings. Type of economic evaluation Cost-utility analysis Study objective This study assessed the cost-effectiveness of adding memantine to the usual cholinesterase inhibitor treatment for patients with Alzheimer's disease. Interventions A cholinesterase inhibitor, donepezil, rivastigmine, or galantamine, was compared against memantine plus a cholinesterase inhibitor. Location/setting Canada/community

2012 NHS Economic Evaluation Database.

194. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands

, in the Netherlands. CRD commentary Interventions: Memantine was appropriately compared with no pharmacological treatment. The authors stated that galantamine was another medical treatment for Alzheimer’s disease, but was not directly comparable. Effectiveness/benefits: The clinical data appear to have been from appropriate sources. The treatment effect was from a pooled analysis of clinical trials which should have ensured high internal validity. Other data were adjusted for the Netherlands, using a large local

Full Text available with Trip Pro

2012 NHS Economic Evaluation Database.

195. Dementia

on the National Institute for Care and Health Excellence (NICE) guidelines Dementia: supporting people with dementia and their carers in health and social care [ ] and Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset [ ], the NICE Technology Appraisal Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease [ ], the European Federation of Neurological Societies (EFNS-ENS) Guidelines on the diagnosis and management of disorders (...) . May 2011 — minor update. The 2011/2012 QOF indicators and the 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011. April 2011 — minor update. Text added to reflect new recommendations from NICE regarding acetylcholinesterase inhibitors and memantine: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease . Issued in June 2011. July 2010 — minor update. The NICE quality standard relating to dementia have been added

2016 NICE Clinical Knowledge Summaries

196. Non-pharmacological Interventions for Behavioral Symptoms of Dementia

-pharmacological Interventions for Behavioral Symptoms of Dementia Evidence-based Synthesis Program of the effects of bright light therapy, physical activity, tactile stimulation, and the use of cholinesterase inhibitors (donepezil, galantamine, rivastigmine, and tacrine) on cognition, affective behavior, and sleep-wake rhythm in persons with dementia. The review attempted to quantify pooled effect sizes for each form of intervention, although the analysis was limited by substantial heterogeneity between

2011 Veterans Affairs Evidence-based Synthesis Program Reports

197. Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study

provided by (Responsible Party): Cyndya Shibao, Vanderbilt University Medical Center Study Details Study Description Go to Brief Summary: Investigators will test the hypothesis that chronic restoration of vagal nerve activity with a central acetylcholinesterase inhibitor improves insulin sensitivity and reduces adipose tissue oxidation in obese African American Women compared to white women. Condition or disease Intervention/treatment Phase Insulin Sensitivity Oxidative Stress Drug: Galantamine Drug (...) : Placebo Phase 1 Detailed Description: Investigators will test the hypothesis that chronic restoration of parasympathetic nervous system (PNS) activity with a central acetylcholinesterase inhibitor improves insulin sensitivity and reduces adipose tissue oxidation in obese African American women (AAW) compared to white women (WW). A cross-over study will be performed in matched cohorts of AAW and white women subjected to chronic central acetylcholinesterase inhibition with galantamine versus placebo

2017 Clinical Trials

198. Study of LM11A-31-BHS in Mild-moderate AD Patients

for a participation in a 6-month clinical trial Ability to swallow capsules Stable pharmacological treatment of any other chronic condition for at least one month prior to screening Stable treatment with one of the acetylcholinesterase inhibitors donepezil (Aricept ®), galantamine (Razadyne®), or rivastigmine (Exelon) or the partial NMDA receptor antagonist with memantine (Namenda®) at least 3-months before baseline Visit or Combination of both treatments mentioned above No regular intake of prohibited

2017 Clinical Trials

199. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease. (PubMed)

principles has provided templates to design synthetic drugs in AD e.g. rivastigmine, phenserine, eptastigmine based on chemical structure of physostigmine of Physostigma venenosum Balf. Even ZT-1 a prodrug of Hup A and memogain a prodrug of galantamine has achieved new direction in drug development in AD. All these first-line cholinesterase-inhibitors are used as symptomatic treatments in AD. Single modality of "One-molecule-one-target" strategy for treating AD has failed and so future therapies

2017 Journal of Ethnopharmacology

200. Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking. (PubMed)

. More than 40 pharmacotherapies were reviewed including conventional pharmacotherapies-NRT, bupropion, and varenicline (all approved by the U.S. Food and Drug Administration as first-line treatment of smoking cessation)-and novel therapies: cytisine, N-acetylcysteine, cycloserine, memantine, baclofen, topiramate, galantamine, and bromocriptine. Studies of combination NRT and varenicline showed the greatest smoking cessation rates. Clonidine and nortriptyline are second-line treatments used when

2017 Pharmacotherapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>